Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Rating of “Hold” by Analysts

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has been given an average recommendation of “Hold” by the five research firms that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $5.50.

MRVI has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Maravai LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Weiss Ratings upgraded shares of Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 29th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $6.00 target price on shares of Maravai LifeSciences in a research report on Friday, May 8th. Wells Fargo & Company raised their target price on shares of Maravai LifeSciences from $4.50 to $5.50 and gave the company an “overweight” rating in a research note on Friday, May 8th. Finally, UBS Group reaffirmed a “reduce” rating on shares of Maravai LifeSciences in a report on Wednesday, June 3rd.

Insider Buying and Selling at Maravai LifeSciences

In related news, General Counsel Kurt Oreshack sold 25,000 shares of the business’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total transaction of $126,500.00. Following the transaction, the general counsel directly owned 360,767 shares in the company, valued at $1,825,481.02. The trade was a 6.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.49% of the stock is owned by insiders.

Institutional Investors Weigh In On Maravai LifeSciences

Several institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada grew its stake in shares of Maravai LifeSciences by 49.0% during the first quarter. Royal Bank of Canada now owns 9,761 shares of the company’s stock worth $27,000 after acquiring an additional 3,209 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Maravai LifeSciences in the 4th quarter valued at approximately $34,000. Insigneo Advisory Services LLC acquired a new stake in Maravai LifeSciences in the 4th quarter worth approximately $34,000. Quantessence Capital LLC acquired a new stake in Maravai LifeSciences in the 3rd quarter worth approximately $31,000. Finally, Stifel Financial Corp purchased a new stake in Maravai LifeSciences during the 4th quarter worth approximately $36,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

Maravai LifeSciences Stock Performance

Shares of NASDAQ MRVI opened at $7.10 on Thursday. Maravai LifeSciences has a 1-year low of $1.99 and a 1-year high of $7.30. The business has a fifty day moving average price of $5.46 and a 200 day moving average price of $4.15. The stock has a market capitalization of $1.83 billion, a P/E ratio of -10.00 and a beta of 0.65. The company has a debt-to-equity ratio of 0.72, a current ratio of 5.91 and a quick ratio of 4.96.

Maravai LifeSciences (NASDAQ:MRVI) last posted its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.06. The company had revenue of $65.84 million for the quarter, compared to analyst estimates of $53.00 million. Maravai LifeSciences had a negative return on equity of 17.87% and a negative net margin of 51.07%. Equities research analysts expect that Maravai LifeSciences will post -0.2 EPS for the current fiscal year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.